- Poster presentation
- Open Access
Juvenile Psoriatic Arthritis (JPsA) clinical features and outcome of 119 patients
© Aviel et al; licensee BioMed Central Ltd. 2008
- Published: 15 September 2008
- Public Health
- Distinct Group
- Single Center
- ILAR Criterion
To determine the long-term outcome of a single center cohort of children with JPsA.
Clinical records of 122 patients meeting the Vancouver or ILAR criteria for JPsA were reviewed. Patients were divided into 4 groups depending on their clinical features: a)Oligoarticular, b)RF(-) polyarticular, c)RF(+) polyarticular and d)enthesitis related arthritis (ERA). Patient characteristics and clinical features at onset and during follow-up were determined.
The cohort consisted of 119 patients, 59(49.6%) had polyarticular course, 54(47.8%) were RF(-) and 4(3.3%) RF(+), 44 patients(38.3%) had oligoarticular course and 16(13.4%) ERA.
At diagnosis patients with ERA were older as compared to patients with oligoarticular and polyarticular course (11.6 ± 2.2 years vs 7.7 ± 4.3 years and 7.1 ± 4.5 years respectively p = 0.001).
Patients with polyarticular course had more MCP, PIP and wrist involvement when compared to patients with oligoarticular course and with ERA (p < 0.001 for all).
Patients with ERA had significantly more hip and sacroiliac involvement compared to the other groups (p < 0.001 for both).
Nail changes was seen in 66 patients (57%) and was associated with DIP involvement at presentation (p = 0.0034).
Time to first inactive disease period on but not off therapy was significantly longer among patients with polyarticular disease when compared to the oligoarticular and the ERA groups (p = 0.016 and p = 0.48 respectively).
Patients with polyarticular had more contracture during follow-up when compared to patients with oligoarticular and with ERA (p = 0.01)
Patients with JPsA compromised from three distinct group of patients.
Most patients with JPsA will achieve inactive disease and only minority will have long lasting contracture.
This article is published under license to BioMed Central Ltd.